Last €27.71 EUR
Change Today +0.218 / 0.79%
Volume 0.0
EII On Other Exchanges
Symbol
Exchange
Tokyo
OTC US
OTC US
Frankfurt
As of 2:21 AM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

eisai co ltd (EII) Snapshot

Open
€27.66
Previous Close
€27.49
Day High
€27.71
Day Low
€27.60
52 Week High
05/15/13 - €35.48
52 Week Low
02/6/14 - €26.60
Market Cap
8.2B
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
296.6M
EX-Date
03/27/14
P/E TM
--
Dividend
€154.78
Dividend Yield
3.95%
Current Stock Chart for EISAI CO LTD (EII)

Related News

No related news articles were found.

eisai co ltd (EII) Related Businessweek News

No Related Businessweek News Found

eisai co ltd (EII) Details

Eisai Co., Ltd. manufactures and sells pharmaceutical products worldwide. The company offers oncology-related products, such as Halaven, an anticancer agent; Aloxi, an antiemetic agent; Dacogen, a DNA methylation inhibitor; and Fragmin, an injectable anticlotting agent, as well as Symbenda/Treakisym, a treatment for low-grade non-Hodgkin's lymphoma and other types of lymphatic cancer. It also provides Aricept, an anti-Alzheimer's agent; Pariet/AcipHex, a proton-pump inhibitor; and Humira, a human anti-TNF-a monoclonal antibody. In addition, the company offers epilepsy products comprising Zonegran, Zebinix, and Fycompa, which are antiepileptic agents; and Inovelon/BANZEL for the treatment of Lennox-Gastaut syndrome. Further, it provides Methycobal, a peripheral neuropathy treatment; Warfarin, an oral anticoagulant; Actonel, an osteoporosis treatment; Selbex for the treatment of gastritis/gastric ulcer; consumer healthcare (over-the-counter) products, which include vitamin B2 preparation Chocola BB Plus; BELVIQ, an antiobesity agent; and Stronger Neo-Minophagen C/Glycyron tablets for liver disease/allergic disease treatment. Additionally, the company is involved in the research and development of various products under the areas of oncology and supportive care, vascular and immunological reaction, gastrointestinal and hepatic disorders, and neurology. It has collaboration agreement with Biogen Idec to develop and commercialize Alzheimer's disease treatments. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was founded in 1941 and is headquartered in Tokyo, Japan.

10,495 Employees
Last Reported Date: 06/21/13
Founded in 1941

eisai co ltd (EII) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

eisai co ltd (EII) Key Developments

Eisai Launches Halaven in Lebanon

Eisai has announced the launch of Halaven (eribulin) in Lebanon. Halaven is approved in Lebanon for the treatment of locally advanced or metastatic breast cancer patients who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. In Lebanon, Eisai is partnered with Lebanese company Abela Freres.

Eisai Co., Ltd. Launches New Energy Drink Joma

Eisai Co., Ltd. announced that it launched its new energy drink, Joma®, in Japan. With the slogan 'Cast a spell of happiness', Joma is an energy drink designed to conjure up the image of a witch, whose powers transcend human abilities. The product's name, when read backwards, is the Japanese word for 'witch' (majo), and the package's design is the image of a dark red can being held by a witch's hand, enhancing the impact of the product. Joma is a carbonated energy drink classified by the Japanese Ministry of Health, Labour and Welfare as a Food with Nutrient Function Claims (Vitamin B 6) that contains arginine, ginseng extract, guarana extract and caffeine in addition to the B vitamins that the Chocola BB brand is well-known for. With its ginger base, Joma is easy to drink with a refreshing after-taste, and has a reduced calorie count of only 33 kcal per bottle. It is for people who want to lift their spirits and display even greater potential than usual.

Eisai Co., Ltd. Enters into Collaboration with Liverpool School of Tropical Medicine and University of Liverpool to Discover Novel Anti-Wolbachia Targeted Anti-Filarial Drugs

Eisai Co., Ltd. announced that it has entered a collaboration with the Liverpool School of Tropical Medicine (LSTM) and University of Liverpool (UoL) to jointly identify new drugs effective against lymphatic filariasis and onchocerciasis (river blindness), both major types of filariasis. Under the collaboration, Eisai will work with LSTM and UoL to identify and develop novel drug candidates that efficiently eliminate the bacteria Wolbachia. Eisai and its collaboration partners will focus on two of these six proposed types and aim to identify a single candidate for potential drug development within one to two years. This unique approach was also evaluated and subsequently awarded a two-year grant by the Global Health Innovative Technology Fund.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EII:GR €27.71 EUR +0.218

EII Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cubist Pharmaceuticals Inc $64.74 USD +0.79
Forest Laboratories Inc $91.04 USD +1.46
Salix Pharmaceuticals Ltd $102.79 USD +1.73
Santen Pharmaceutical Co Ltd ¥4,595 JPY -60.00
Shire PLC 2,925 GBp +25.00
View Industry Companies
 

Industry Analysis

EII

Industry Average

Valuation EII Industry Range
Price/Earnings 26.4x
Price/Sales 2.0x
Price/Book 2.3x
Price/Cash Flow 27.4x
TEV/Sales 1.3x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EISAI CO LTD, please visit www.eisai.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.